Olema Reports Promising Phase 1b/2 Data for Palazestrant Plus Ribociclib in Advanced Breast Cancer
Reuters
Oct 18
Olema Reports Promising Phase 1b/2 Data for Palazestrant Plus Ribociclib in Advanced Breast Cancer
Olema Pharmaceuticals Inc. has announced updated data from a Phase 1b/2 clinical study evaluating palazestrant (OP-1250) in combination with ribociclib for patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. The results, which will be presented at the European Society for Medical Oncology (ESMO) Congress 2025 on October 20, showed that the combination demonstrated activity across all dose cohorts and subgroups. The median progression-free survival $(PFS)$ was 15.5 months in the 120 mg palazestrant cohort overall. Among patients previously treated with CDK4/6 inhibitors, median PFS was 9.2 months for those with ESR1 wild-type tumors and 13.8 months for those with ESR1 mutant tumors. The regimen continued to show favorable tolerability and a safety profile consistent with known profiles of the individual drugs. These findings support the ongoing Phase 3 OPERA-02 trial, which is assessing the combination as a frontline therapy in advanced or metastatic breast cancer.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Olema Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9547706-en) on October 18, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.